Grazina Raquel, Gano Lurdes, Sebestík Jaroslav, Amelia Santos M
Centro Química Estrutural, Instituto Superior Técnico-UTL, Av. Rovisco Pais, 1049-001 Lisboa, Portugal.
J Inorg Biochem. 2009 Feb;103(2):262-73. doi: 10.1016/j.jinorgbio.2008.10.014. Epub 2008 Oct 30.
Two new tris-hydroxypyridinone based compounds (KEMPPr(3,4-HP)(3) and KEMPBu(3,4-HP)(3)) have been developed and studied as strong sequestering agents for iron and the group III of metal ions, aimed as potential pharmacological applications on metal-chelation therapy. Their structure is based on the KEMP acid scaffold to which three 3-hydroxy-4-pyridinone chelating moieties are attached via two different size spacers. After the preparation and characterization of the compounds their physico-chemical properties were studied, in relation with their metal binding affinity and lipophilicity. The KEMPPr(3,4-HP)(3) ligand was also bioassayed to evaluate its in vivo metal sequestering capacity from most organs using an animal model overload with (67)Ga. These studies showed that, for both in solution and in vivo conditions, the compounds have higher metal chelating efficacy than Deferriprone, the commercially available iron chelator in medical application, thus some perspectives are envisaged as potential pharmaceutical drug candidates for chelating therapy.
两种基于三羟基吡啶酮的新化合物(KEMPPr(3,4-HP)(3) 和 KEMPBu(3,4-HP)(3))已被开发并作为铁和 III 族金属离子的强螯合剂进行研究,旨在用于金属螯合疗法的潜在药理学应用。它们的结构基于 KEMP 酸支架,三个 3-羟基-4-吡啶酮螯合部分通过两个不同大小的间隔基连接到该支架上。在制备和表征化合物后,研究了它们的物理化学性质,以及它们与金属结合亲和力和亲脂性的关系。还使用 (67)Ga 过载动物模型对 KEMPPr(3,4-HP)(3) 配体进行了生物测定,以评估其从大多数器官中螯合体内金属的能力。这些研究表明,在溶液和体内条件下,这些化合物的金属螯合功效均高于医学应用中市售的铁螯合剂去铁酮,因此有望成为螯合疗法的潜在候选药物。